Quarterly guidance

Quarterly guidance
No quarterly guidance was given.

Annual guidance

Non-GAAP EPS
$6.35 to $6.55
Legacy portfolio revenue
Decrease of 3% to 5%
Eliquis revenue growth
20% to 25%

Outlook

Growth Portfolio
Eight medicines are now annualizing over $1 billion in sales.
Manufacturing
Investing $2.3 billion in a Houston campus and $170 million in Indiana for radiopharmaceuticals.
Pipeline
Expecting Phase III data for Milvexian in secondary stroke prevention and lupus before year-end.
Productivity
On track to achieve $2 billion in efficiencies by the end of 2027.
Capital Allocation
Business development remains a top priority, with a focus on therapeutic areas where the company has scientific and commercial strength.
AI Strategy
Aiming for a 20% to 30% reduction in drug testing timelines through AI integration.